ClinicalTrials.gg
CompletedNCT06775327Updated Jun 11, 2025

Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants

A Phase 1 interventional study of INCB000631 and Placebo in Healthy Participants, sponsored by Incyte Corporation. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-11.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

This study will be conducted to assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics, and Food Effect of INCB000631 When Administered Orally to Healthy Adult Participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • INCB000631
03

In context

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comprehend and willingness to sign a written ICF for the study.
  • Aged 19 to 55 years, inclusive, at the time of signing the ICF.
  • between 18.0 and 32.0 kg/m2, inclusive, at screening. Note: Only up to 25% of the participants may be enrolled with a body mass index > 30 to ≤ 32.0 kg/m2.
  • No findings on screening evaluations (clinical, laboratory [except lipids], and ) as determined by the investigator. If the investigator has questions about clinically significant findings, the medical monitor should be consulted.
  • Ability to swallow and retain oral tablets.
  • Willingness to avoid pregnancy or fathering children based on the protocol defined criteria.

Exclusion criteria

Exclusion Criteria:

  • History of uncontrolled or unstable respiratory, renal, gastrointestinal, endocrine, pulmonary, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening.
  • History of an disease (eg, myasthenia gravis).
  • History of cardiovascular, cerebrovascular, cerebral, peripheral vascular, or thrombotic disease or uncontrolled hypertension.
  • High blood pressure (systolic blood pressure > 140 mm Hg or diastolic blood pressure > 90 mm Hg at screening, confirmed by repeat testing).
  • Confirmed resting pulse (up to 3 measurements) \< 40 bpm or > 100 bpm at screening for vital signs.
  • History or presence of an abnormal before initial dose administration that, in the investigator's opinion, is . Participants with a interval > 450 milliseconds (males) or > 470 milliseconds (females), QRS interval > 120 milliseconds, or PR interval > 220 milliseconds will be excluded.

In the event a value is exclusionary, a single ECG will be repeated twice, and an average of the 3 readings will be used to determine if a participant should be excluded.

  • Presence or history of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn disease or chronic pancreatitis).
  • History of within 5 years of screening, with the exception of cured basal cell or squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.
  • History of other malignancy within 2 years of screening (with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy) or cancers from which the participant has been disease-free for \< 1 year after treatment with curative intent.
  • Current or recent (within 3 months of screening) clinically significant gastrointestinal disease or surgery (including cholecystectomy; excluding appendectomy and hernia repair) that could affect the absorption of study drug.
  • , WBC count, count, or less than the laboratory lower limit of normal at screening or at check-in, confirmed by repeat testing, that is considered clinically significant in the opinion of the investigator to be exclusionary.
  • Hepatic transaminases ( and AST), ALP, or total > 1.25 × the laboratory-defined at screening or at check-in, confirmed by repeat testing (except participants with Gilbert disease, for whom total bilirubin must be ≤ 2.0 × ULN).
  • Any major surgery within 4 weeks of screening.
  • Donation of blood to a blood bank or participation in a clinical study (except a screening visit) within 4 weeks of screening (within 2 weeks for donation of plasma only).
  • Blood transfusion within 4 months of check-in (Day -1).
  • Chronic, known, or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment (includes latent tuberculosis).
  • Positive test for , , or . Participants whose results are compatible with prior immunization for or immunity due to infection with HBV may be included at the discretion of the investigator.
  • Received a (including attenuated) within 3 months of the planned start of the study drug or anticipation of need for such a vaccine during the study. This includes seasonal influenza vaccines.

Note: Examples of live vaccines include but are not limited to the following: measles, mumps, rubella, chickenpox/zoster, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid.

  • History of significant alcohol use within 3 months of screening, defined as regular alcohol consumption > 21 units per week for males and > 14 units for females (1 unit = one-half pint of beer or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine).
  • Positive urine or breath test for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
  • Ingestion of caffeine- or xanthine-containing products (eg, coffee, tea, cola drinks, energy drinks, and chocolate) within 48 hours before check-in.
  • Consumption of alcoholic beverages, Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices within 48 hours before check-in.
  • History of tobacco or nicotine-containing product use within 1 month of screening.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with another medication or current enrollment in another investigational drug study.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with an inducer or inhibitor of , P-gp, or BCRP (refer to the Certara Drug Interaction Database for prohibited drugs).
  • Current use of prohibited medication as described in the protocol.
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
  • Known or severe reaction to INCB000631 or any of INCB000631 or any SPPL2a inhibitors (refer to the IB).
  • Inability to undergo venipuncture or tolerate venous access (participant has inadequate veins for repeat venipuncture or venous access as determined by the investigator or designee).
  • Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator or designee.
  • Use of prescription drugs (including hormonal ) within 14 days of study drug administration or nonprescription medications/products (including minerals and phytotherapeutics/herbals [including St John's wort]/plant-derived preparations) within 7 days of study drug administration. However, occasional and standard-dose acetaminophen and standard-dose vitamins are permitted. Mega-dose vitamins or supplements are not permissible.
  • Pregnant or breastfeeding.
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • \< 90 mL/min/1.73 m2 based on the site's standard formula at screening. Note: Assessment of eGFR may be repeated once if outside of the reference range.
  • Excessive exercise beyond the activities of daily living (eg, triathlon) within 7 days before check-in (Day -1).
  • History of severe lactose intolerance or food allergies/intolerance to the composition of the standard high-fat breakfast to be served (Cohort G only).
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Cohort A

    INCB000631 or placebo will be administered at the protocol defined dose.

    Drug: INCB000631 · Drug: Placebo

  • Experimental
    Cohort B

    INCB000631 or placebo will be administered at the protocol defined dose.

    Drug: INCB000631 · Drug: Placebo

  • Experimental
    Cohort C

    INCB000631 or placebo will be administered at the protocol defined dose.

    Drug: INCB000631 · Drug: Placebo

  • Experimental
    Cohort D

    INCB000631 or placebo will be administered at the protocol defined dose.

    Drug: INCB000631 · Drug: Placebo

  • Experimental
    Cohort E

    INCB000631 or placebo will be administered at the protocol defined dose.

    Drug: INCB000631 · Drug: Placebo

  • Experimental
    Optional Cohort F

    INCB000631 or placebo will be administered at the protocol defined dose.

    Drug: INCB000631 · Drug: Placebo

  • Experimental
    Cohort G Treatment A

    INCB000631 will be administered at the protocol defined dose.

    Drug: INCB000631

  • Experimental
    Cohort G Treatment B

    INCB000631 will be administered at the protocol defined dose.

    Drug: INCB000631

Interventions

  • DrugINCB000631

    Oral; Tablet

  • DrugPlacebo

    Oral; Tablet

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as any adverse event, either reported for the first time or the worsening of a pre-existing event, occurring after dose of study treatment.

    Time frame: Up to Day 41

  2. PK for plasma INCB000631: Cmax

    Maximum Observed Plasma Concentration of INCB000631.

    Time frame: Up to Day 14

  3. PK for plasma INCB000631: tmax

    Time to maximum plasma concentration of INCB000631.

    Time frame: Up to Day 14

  4. PK for plasma INCB000631: AUC(0-t)

    Area under the single-dose plasma concentration-time curve up to the last measurable plasma concentration of INCB000631.

    Time frame: Up to Day 14

  5. PK for plasma INCB000631: AUC 0-∞

    Area under the single-dose plasma concentration-time curve from 0 to Infinity of INCB000631.

    Time frame: Up to Day 14

Secondary outcomes

  1. PK for plasma INCB000631: t1/2

    Apparent terminal phase disposition half-life of INCB000631.

    Time frame: Up to Day 14

  2. PK for plasma INCB000631: CL/F

    Dose clearance of INCB000631.

    Time frame: Up to Day 14

  3. PK for plasma INCB000631: Vz/F

    Apparent oral dose volume of distribution of INCB000631.

    Time frame: Up to Day 14

  4. PK for plasma INCB000631: λz

    Apparent terminal-phase disposition rate constant of INCB000631.

    Time frame: Up to Day 14

  5. PK for urine INCB000631: Ae96h

    Amount of INCB000631 excreted in the urine over 96 hours.

    Time frame: Up to Day 14

  6. PK for urine INCB000631: fe

    Percent of INCB000631 excreted in the urine.

    Time frame: Up to Day 14

  7. PK for urine INCB000631: CLR

    Renal clearance of INCB000631.

    Time frame: Up to Day 14

07

Study locations

1 site
  • Celerion, Inc
    Lincoln, Nebraska 68502, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in May 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 15, 2025
StartActual
Feb 13, 2025
Primary completionActual
May 28, 2025
CompletionActual
May 28, 2025
Last update
Jun 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06775327
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Feb 13, 2025
Primary completion
May 28, 2025
Completion
May 28, 2025
Last update
Jun 11, 2025

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion